Central Nervous System Drugs Market Along With Covid-19 Impact Analysis and Drug Descriptions, Clinical Review Outlook – 2023 | Biogen Inc, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Pfizer Inc

The latest market report on Central Nervous System Drugs Market 2019 offers an in-depth analysis of this business vertical involving key information concerning industry deliverables, predominantly market tendencies, market size, market share, present valuation, and profits estimations for the estimated period. The brief information regarding the industry also analyzes and elucidates the Central Nervous System Drugs Market growth rate in the forecast timeline, incited by certain catalysts.

The global Central Nervous System Drugs Market is expected to grow from $123.4 billion in 2019 to $136.7 billion in 2020 at a compound annual growth rate (CAGR) of 10.8%. This growth is mainly due to the COVID-19 outbreak and the neuroinvasive nature of the virus. The CNS is more prone to the viral infection. The virus affects the senses of smell and taste and therefore it is important to curb the interaction between the viral protein and the human receptor, and this factor is driving the demand for CNS drugs. The market is then expected to recover and grow at a CAGR of 6% from 2021 and reach $160.4 billion in 2023.

Central Nervous System Drugs Market: Overview

Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson’s disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%. For instance, in 2017, Michael J. Fox Foundation for Parkinson’s Research collaborated with specialty drug maker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson’s disease. Biogen, a leading CNS drug maker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer’s disease research.

The central nervous system drugs market consists sales of central nervous system drugs and related services by entities (organizations, sole traders and partnerships) that produce central nervous system drugs to treat brain and spinal cord diseases. This industry includes establishments that produce nervous system drugs, pain reducing analgesics, anti-Parkinson drugs to treat Parkinson’s disease, anticonvulsant anti-epileptics drugs to control epileptic seizures, anesthetics and other drugs such as muscle relaxants, antiemetics.

Make an Inquiry about this report:

https://bit.ly/3f9e2u0

Major players in the Central Nervous System Drugs Market are Biogen Inc; F. Hoffmann-La Roche Ltd; Johnson & Johnson; Pfizer Inc; Novartis AG, and others.

Industry News: Tuesday, October 23, 2018

BAIN CAPITAL AND PFIZER CREATE CEREVEL THERAPEUTICS, NEW CNS COMPANY

Bain Capital, LP and Pfizer Inc. (NYSE: PFE) today announced the creation of Cerevel Therapeutics, LLC (“Cerevel”), a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). Pfizer is contributing a portfolio of pre-commercial neuroscience assets to Cerevel, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Funds affiliated with Bain Capital Private Equity and Bain Capital Life Sciences have committed $350 million with the ability to provide additional capital should it be needed in the future.

Cerevel will seek to expand treatment options in a therapeutic area where there is an urgent unmet need for patients. Bain Capital and Pfizer will support Cerevel in building a dedicated team of CNS scientists and life sciences executives with extensive experience in clinical development of potential therapies for patients who have neurological and neuropsychological diseases. The most advanced assets in the portfolio are a D1 partial agonist which will likely enter Phase III in 2019 to treat the symptoms of Parkinson’s disease, and a Phase II ready selective GABA 2/3 agonist which will initially be studied for epilepsy. The company also has active programs in early development, discovery and a research program in neuroinflammation.

Geographic scope:
For a comprehensive understanding of market dynamics, the global Central Nervous System Drugs Market is analyzed across key geographies namely: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

Inquiry for discount (Exclusive offer: get flat 20% discount):

https://bit.ly/3hmchfg

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends, and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider Central Nervous System Drugs market and compares it with other markets.

- The market characteristics section of the report defines and explains the market.

- The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID 19 virus, and forecasting its recovery.

- Market segmentations break down the market into submarkets.

- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID 19 for all regions, key developed countries, and major emerging markets.

- The competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals that have shaped the market in recent years are identified.

- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

- The Central Nervous System Drugs market section of the report gives context. It compares the Central Nervous System Drugs market with other segments of the support activities for the mining market by size and growth, historic, and forecast. It analyses GDP proportion, expenditure per capita, and Central Nervous System Drugs indicators comparison.

Browse in-depth and report summary TOC on "Central Nervous System Drugs Market"

https://bit.ly/2Yqyccd

We Offer Customization On Report Based On Specific Client Requirement:

- Country Level analysis for any 5 countries of your choice.
- Competitive analysis of any 5 key market players.
- 40 analyst hours to cover any other data point.

Note - All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

You Can Browse Following Related Reports

COVID-19 Impact On Central Nervous System Therapeutic Market, Global Research Reports 2020-2021
https://www.marketinsightsreports.com/reports/05292052023/covid-19-impact-on-central-nervous-system-therapeutic-market-global-research-reports-2020-2021?Mode=56

COVID-19 Impact On Global Central Nervous System Biomarkers Market Size, Status And Forecast 2020-2026
https://www.marketinsightsreports.com/reports/06092082567/covid-19-impact-on-global-central-nervous-system-biomarkers-market-size-status-and-forecast-2020-2026?Mode=56

COVID-19 Impact On Central Nervous System Treatment Market, Global Research Reports 2020-2021
https://www.marketinsightsreports.com/reports/05292052024/covid-19-impact-on-central-nervous-system-treatment-market-global-research-reports-2020-2021?Mode=56

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports 
sales@marketinsightsreports.com | irfan@marketinsightsreports.com
Phone: + 1704 266 3234 | +91-750-707-8687

About Us:

MarketInsightsReports is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. MarketInsightsReports offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, water, advanced materials, and much more.

This release was published on openPR.